## IN THE CLAIMS

The status of each claim is listed below.

Claims 1-81: Canceled.

82. (New) A method of effecting in a subject at least one member selected from the group consisting of promoting hydration of mucosal surfaces, promoting ocular hydration, promoting corneal hydration, promoting mucus clearance in mucosal surfaces, restoring mucosal defense, preventing ventilator-induced pneumonia, inducing sputum for diagnostic purposes, blocking sodium channels, treating chronic bronchitis, treating cystic fibrosis, treating sinusitis, treating vaginal dryness, treating dry eye, treating Sjogren's disease, treating distal intestinal obstruction syndrome, treating dry skin, treating esophagitis, treating dry mouth (xerostomia), treating nasal dehydration, treating chronic obstructive pulmonary disease, treating emphysema, treating pneumonia, treating constipation, treating chronic diverticulitis, treating rhinosinusitis, treating asthma, treating primary ciliary dyskinesia, and treating otitis media,

comprising:

administering to the subject an effective amount of a compound represented by formula (I):

$$\text{(structure: pyrazine ring with positions 1-6; N at 1 and 4; X at 6, Y at 5, NHR}^2\text{ at 3; C2 bears C(=O)-N=C(-NHR}^1\text{)-N(R}^3\text{)(R}^4\text{)})}$$

X—6—N(1)—2—C(=O)—N=C(—NHR¹)—N(—R³)(—R⁴)

(I)

wherein

X is hydrogen, halogen, trifluoromethyl, lower alkyl, unsubstituted or substituted phenyl, lower alkyl-thio, phenyl-lower alkyl-thio, lower alkyl-sulfonyl, or phenyl-lower alkyl-sulfonyl;

Y is hydrogen, hydroxyl, mercapto, lower alkoxy, lower alkyl-thio, halogen, lower alkyl, unsubstituted or substituted mononuclear aryl, or $-N(R^2)_2$;

R^1 is hydrogen or lower alkyl;

each R^2 is, independently, $-R^7$, $-(CH_2)_m-OR^8$, $-(CH_2)_m-NR^7R^{10}$,

$-(CH_2)_n(CHOR^8)(CHOR^8)_n-CH_2OR^8$, $-(CH_2CH_2O)_m-R^8$,

$-(CH_2CH_2O)_m-CH_2CH_2NR^7R^{10}$, $-(CH_2)_n-C(=O)NR^7R^{10}$, $-(CH_2)_n-Z_g-R^7$, $-(CH_2)_m-NR^{10}-$

$CH_2(CHOR^8)(CHOR^8)_n-CH_2OR^8$, $-(CH_2)_n-CO_2R^7$, or

$$-(CH_2)_n-\text{(1,3-dioxolane ring bearing two } R^7 \text{ at the 2-position)}$$

R^3 and R^4 are each, independently, hydrogen, a group represented by formula (A), lower alkyl, hydroxy lower alkyl, phenyl, phenyl-lower alkyl, (halophenyl)-lower alkyl,

lower-(alkylphenylalkyl), lower alkoxyphenyl)-lower alkyl, naphthyl-lower alkyl, or pyridyl-lower alkyl, with the proviso that at least one of R^3 and R^4 is a group represented by formula (A):

$$—(C(R^L)_2)_o—x—(C(R^L)_2)_p—\underset{Q—Q}{\overset{Q=Q}{\diagdown}}\underset{(R^6)_4}{\overset{OH}{\diagup}}Q \qquad (A)$$

wherein

each R^L is, independently, $-R^7$, $-(CH_2)_n-OR^8$, $-O-(CH_2)_m-OR^8$,

$-(CH_2)_n-NR^7R^{10}$, $-O-(CH_2)_m-NR^7R^{10}$, $-(CH_2)_n(CHOR^8)(CHOR^8)_n-CH_2OR^8$,

$-O-(CH_2)_m(CHOR^8)(CHOR^8)_n-CH_2OR^8$, $-(CH_2CH_2O)_m-R^8$,

$-O-(CH_2CH_2O)_m-R^8$, $-(CH_2CH_2O)_m-CH_2CH_2NR^7R^{10}$,

$-O-(CH_2CH_2O)_m-CH_2CH_2NR^7R^{10}$, $-(CH_2)_n-C(=O)NR^7R^{10}$,

$-O-(CH_2)_m-C(=O)NR^7R^{10}$, $-(CH_2)_n-(Z)_g-R^7$, $-O-(CH_2)_m-(Z)_g-R^7$,

$-(CH_2)_n-NR^{10}-CH_2(CHOR^8)(CHOR^8)_n-CH_2OR^8$,

$-O-(CH_2)_m-NR^{10}-CH_2(CHOR^8)(CHOR^8)_n-CH_2OR^8$,

$-(CH_2)_n-CO_2R^7$, $-O-(CH_2)_m-CO_2R^7$, $-OSO_3H$, -O-glucuronide, -O-glucose, or

$$—O\left(CH_2\right)_m\overset{O}{\underset{O}{\diagdown}}\overset{R^7}{\underset{R^7}{\diagup}} \quad \text{or} \quad —(CH_2)_n—\overset{O}{\underset{O}{\diagdown}}\overset{R^7}{\underset{R^7}{\diagup}} \;;$$

each x is, independently, O, NR^7, C=O, CHOH, C=N-R^6, or represents a single bond;

each o is, independently, an integer from 0 to 10;

each p is, independently, an integer from 0 to 10;

with the proviso that (a) the sum of o and p in each contiguous chain is from 1 to 10 when x is O, NR^7, C=O, or C=N-R^6 or (b) that the sum of o and p in each contiguous chain is from 4 to 10 when x represents a single bond;

each R^6 is, independently, -R^7, -OH, -OR^{11}, -N(R^7)$_2$, -(CH$_2$)$_m$-OR^8,

-O-(CH$_2$)$_m$-OR^8, -(CH$_2$)$_n$-NR^7R^{10}, -O-(CH$_2$)$_m$-NR^7R^{10},

-(CH$_2$)$_n$(CHOR^8)(CHOR^8)$_n$-CH$_2$OR^8, -O-(CH$_2$)$_m$(CHOR^8)(CHOR^8)$_n$-CH$_2$OR^8,

-(CH$_2$CH$_2$O)$_m$-R^8, -O-(CH$_2$CH$_2$O)$_m$-R^8, -(CH$_2$CH$_2$O)$_m$-CH$_2$CH$_2$NR^{7}R^{10},

-O-(CH$_2$CH$_2$O)$_m$-CH$_2$CH$_2$NR^{7}R^{10}, -(CH$_2$)$_n$-C(=O)NR^{7}R^{10},

-O-(CH$_2$)$_m$-C(=O)NR^{7}R^{10}, -(CH$_2$)$_n$-(Z)$_g$-R^7, -O-(CH$_2$)$_m$-(Z)$_g$-R^7,

-(CH$_2$)$_n$-NR^{10}-CH$_2$(CHOR^8)(CHOR^8)$_n$-CH$_2$OR^8,

-O-(CH$_2$)$_m$-NR^{10}-CH$_2$(CHOR^8)(CHOR^8)$_n$-CH$_2$OR^8,

-(CH$_2$)$_n$-CO$_2$R^7, -O-(CH$_2$)$_m$-CO$_2$R^7, -OSO$_3$H, -O-glucuronide, -O-glucose,

wherein when two R^6 are -OR^{11} and are located adjacent to each other on a phenyl ring, the alkyl moieties of the two R^6 may be bonded together to form a methylenedioxy group;

each R^7 is, independently, hydrogen or lower alkyl;

each R^8 is, independently, hydrogen, lower alkyl, -C(=O)-R^{11}, glucuronide, 2-tetrahydropyranyl, or

$$\text{(chemical structure: pyranose ring bearing } CO_2R^{11}, OCOR^{11}, OCOR^{11}, OCOR^{11}, \text{ and an } O\text{-methyl group)} \quad ;$$

each R^9 is, independently, $-CO_2R^7$, $-CON(R^7)_2$, $-SO_2CH_3$, or $-C(=O)R^7$;

each R^{10} is, independently, $-H$, $-SO_2CH_3$, $-CO_2R^7$, $-C(=O)NR^7R^9$,

$-C(=O)R^7$, or $-CH_2-(CHOH)_n-CH_2OH$;

each Z is, independently, CHOH, C(=O), $CHNR^7R^{10}$, $C=NR^{10}$, or NR^{10};

each R^{11} is, independently, lower alkyl;

each g is, independently, an integer from 1 to 6;

each m is, independently, an integer from 1 to 7;

each n is, independently, an integer from 0 to 7;

each Q is, independently, $C-R^5$, $C-R^6$, or a nitrogen atom, wherein at

most three Q in a ring are nitrogen atoms;

or a pharmaceutically acceptable salt thereof, and

inclusive of all enantiomers, diastereomers, and racemic mixtures thereof.

83. (New) The method of Claim 82, wherein promoting hydration of mucosal

surfaces is effected.

84. (New) The method of Claim 82, promoting ocular hydration is effected.

85. (New) The method of Claim 82 promoting corneal hydration is effected.

86. (New) The method of Claim 82, promoting mucus clearance in mucosal surfaces is effected.

87. (New) The method of Claim 82, restoring mucosal defense is effected.

88. (New) The method of Claim 82, preventing ventilator-induced pneumonia is effected.

89. (New) The method of Claim 82, inducing sputum for diagnostic purposes is effected.

90. (New) The method of Claim 82, blocking sodium channels is effected.

91. (New) The method of Claim 82, treating chronic bronchitis is effected.

92. (New) The method of Claim 82, treating cystic fibrosis is effected.

93. (New) The method of Claim 82, treating sinusitis is effected.

94. (New) The method of Claim 82, treating vaginal dryness is effected.

95. (New) The method of Claim 82, treating dry eye is effected.

96. (New) The method of Claim 82, treating Sjogren's disease is effected.

97. (New) The method of Claim 82, treating distal intestinal obstruction syndrome is effected.

98. (New) The method of Claim 82, treating dry skin, treating esophagitis is effected.

99. (New) The method of Claim 82, treating dry mouth (xerostomia) is effected.

100. (New) The method of Claim 82, treating nasal dehydration is effected.

101. (New) The method of Claim 82, treating chronic obstructive pulmonary disease is effected.

102. (New) The method of Claim 82, treating emphysema is effected.

103. (New) The method of Claim 82, treating pneumonia is effected.

104. (New) The method of Claim 82, treating constipation is effected.

105. (New) The method of Claim 82, treating chronic diverticulitis is effected.

106. (New) The method of Claim 82, treating rhinosinusitis is effected.

107. (New) The method of Claim 82, treating asthma is effected.

108. (New) The method of Claim 82, treating primary ciliary dyskinesia is effected.

109. (New) The method of Claim 82, treating otitis media is effected.

110. (New) The method of Claim 82, wherein the nasal dehydration is brought on by administering dry oxygen to the subject.

111. (New) The method of Claim 82, wherein the compound is administered orally or via a suppository or enema.

112. (New) The method of Claim 82, wherein Y is $-NH_2$.

113. (New) The method of Claim 112, wherein R^2 is hydrogen.

114. (New) The method of Claim 113, wherein R^1 is hydrogen.

115. (New) The method of Claim 114, wherein X is chlorine.

116. (New) The method of Claim 115, wherein R^3 is hydrogen.

117. (New) The method of Claim 116, wherein each R^L is hydrogen.

118. (New) The method of Claim 117, wherein o is 4.

119. (New) The method of Claim 118, wherein p is 0.

120. (New) The method of Claim 119, wherein x represents a single bond.

121. (New) The method of Claim 120, wherein each R^6 is hydrogen.

122. (New) The method of Claim 121, wherein at most one Q is a nitrogen atom.

123. (New) The method of Claim 122, wherein no Q is a nitrogen atom.

124 (New) The method of Claim 82, wherein

X is halogen;

Y is $-N(R^7)_2$;

R^1 is hydrogen or C_1-C_3 alkyl; and

R^2 is $-R^7$, $-(CH_2)_m$-OR^7, or $-(CH_2)_n$-CO_2R^7;

R^3 is a group represented by formula (A); and

R^4 is hydrogen, a group represented by formula (A), or lower alkyl;

125. (New) The method of Claim 124, wherein

X is chloro or bromo;

Y is $-N(R^7)_2$;

R^2 is hydrogen or C_1-C_3 alkyl;

at most three R^6 are other than hydrogen as defined above;

at most three R^L are other than hydrogen as defined above; and

at most 2 Q in a ring are nitrogen atoms.

126. (New) The method of Claim 124, wherein Y is $-NH_2$.

127. (New) The method of Claim 126, wherein

R^4 is hydrogen;

at most one R^L is other than hydrogen as defined above;

at most two R^6 are other than hydrogen as defined above; and

at most 1 Q in a ring is a nitrogen atom.

128. (New) The method of Claim 127, wherein no Q in a ring is a nitrogen atom.

129. (New) The method of Claim 127, wherein x is O, NR^7, C=O, CHOH, or C=N-R^6.

130. (New) The method of Claim 127, wherein x represents a single bond.

131. (New) The method of Claim 82, wherein x is O, NR^7, C=O, CHOH, or C=N-R^6.

132. (New) The compound of Claim 82, wherein x represents a single bond.

133. (New) The compound of Claim 82, wherein each R^6 is hydrogen.

134. (New) The method of Claim 82, wherein at most two R^6 are other than hydrogen as defined in Claim 82.

135. (New) The method of Claim 82, wherein one R^6 is other than hydrogen as defined in Claim 82.

136. (New) The method of Claim 82, wherein one R^6 is -OH.

137. (New) The method of Claim 82, wherein each R^L is hydrogen.

138. (New) The method of Claim 82, wherein at most two R^L are other than hydrogen as defined in Claim 82.

139. (New) The method of Claim 82, wherein one R^L is other than hydrogen as defined in Claim 82.

140. (New) The method of Claim 82, wherein x represents a single bond and the sum of o and p is 4 to 6.

141. (New) The method of Claim 82, wherein the compound is represented by the formula

142. (New) The method of Claim 141, wherein the compound is in the form of a pharmaceutically acceptable salt.

143. (New) The method of Claim 142, wherein the compound is in the form of a hydrochloride salt.

144. (New) The method of Claim 142, wherein the compound is in the form of a mesylate salt.

145. (New) The method of Claim 82, wherein the compound is represented by the formula

146. (New) The method of Claim 145, wherein the compound is in the form of a pharmaceutically acceptable salt.

147. (New) The method of Claim 146, wherein the compound is in the form of a hydrochloride salt.

148. (New) The method of Claim 146, wherein the compound is in the form of a mesylate salt.

149. (New) The method of Claim 82, wherein the compound is represented by the formula


150. (New) The method of Claim 149, wherein the compound is in the form of a pharmaceutically acceptable salt.

151. (New) The method of Claim 150, wherein the compound is in the form of a hydrochloride salt.

152. (New) The method of Claim 150, wherein the compound is in the form of a mesylate salt.

153. (New) The method of Claim 82, wherein the compound is represented by the formula


154. (New) The method of Claim 153, wherein the compound is in the form of a pharmaceutically acceptable salt.

155. (New) The method of Claim 154, wherein the compound is in the form of a hydrochloride salt.

156. (New) The method of Claim 154, wherein the compound is in the form of a mesylate salt.

157. (New) The method of Claim 82, wherein the compound is represented by the formula

158. (New) The method of Claim 157, wherein the compound is in the form of a pharmaceutically acceptable salt.

159. (New) The method of Claim 158, wherein the compound is in the form of a hydrochloride salt.

160. (New) The method of Claim 158, wherein the compound is in the form of a mesylate salt.

161. (New) The method of Claim 82, wherein the compound is represented by the formula

162. (New) The method of Claim 161, wherein the compound is in the form of a pharmaceutically acceptable salt.

163. (New) The method of Claim 162, wherein the compound is in the form of a hydrochloride salt.

164. (New) The method of Claim 162, wherein the compound is in the form of a mesylate salt.

165. (New) The method of Claim 82, wherein the compound is in the form of a pharmaceutically acceptable salt.

166. (New) The method of Claim 82, wherein the compound is in the form of a mesylate salt.

167. (New) The method of Claim 82, wherein the compound is administered as a pharmaceutical composition which also comprises a pharmaceutically acceptable carrier.

168. (New) The method of Claim 82, wherein the compound is administered as a composition which also comprises a P2Y2 inhibitor.

169. (New) The method of Claim 82, wherein the compound is administered as a composition which also comprises a bronchodilator.